CD19 CAR T cell product and disease attributes predict leukemia remission durabilityOlivia Finney, Michael C. Jensen, Ben Futrell et al.|Journal of Clinical Investigation|2019Cited by 355
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca Gardner, Michael C. Jensen, Francesco Ceppi et al.|Blood|2019Cited by 287
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyJuliane Gust, Rebecca Gardner, Olivia Finney et al.|Annals of Neurology|2019Cited by 191